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Keypoints: 
-Enrichment of atypical MPL mutations in Essential Thrombocythemia 
-MPLS204P and MPLY591N mutants are weak gain-of-function mutants 
Abstract (191) 
Mutations in signaling molecules of the cytokine receptor axis play a central role in 
myeloproliferative neoplasm (MPN) pathogenesis. Polycythemia Vera is mainly related to 
JAK2 mutations, whereas a wider mutational spectrum is detected in Essential 
Thrombocythemia (ET) with mutations in JAK2, the thrombopoietin receptor (MPL) and the 
calreticulin (CALR) genes. Here, we studied the mutational profile of 17 ET patients negative 
for JAK2V617F, MPLW515K/L and CALR mutations, using Whole Exome Sequencing and 
Next Generation Sequencing (NGS) targeted on JAK2 and MPL. We found several signaling 
mutations including JAK2V617F at very low allele frequency, one homozygous SH2B3 
mutation, one MPLS505N, one MPLW515R and two MPLS204P mutations. In the remaining 
patients, four presented a clonal and seven a polyclonal hematopoiesis, suggesting that certain 
triple negative ETs are not MPNs. NGS on 26 additional triple negative ETs detected only 
one MPLY591N mutation. Functional studies on MPLS204P and MPLY591N revealed that 
they are weak gain-of-function mutants increasing MPL signaling and conferring either TPO 
hypersensitivity or independence to expressing cells, but with a low efficiency. Further 
studies should be performed to precisely determine the frequency of MPLS204 and MPLY591 
mutants in a bigger cohort of MPN.    
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 Introduction 
According to the WHO classification, Essential Thrombocythemia (ET), Polycythemia 
Vera (PV) and Primary Myelofibrosis (PMF) belong to the classical non-BCR-ABL1 
Myeloproliferative Neoplasms (MPNs).1,2 All the non-BCR-ABL1 MPNs are associated with 
persistent and hyper-activation of the JAK2/STAT signaling pathway, but ET and PMF are 
heterogeneous disorders. JAK2V617F is the predominant mutation found in 50%-60% of the 
ET cases.3 Other signaling molecules are mutated in ET including MPL and SH2B3 (LNK). 
The most prevalent MPL mutations in ET and PMF occur on tryptophan 515, an amino acid 
that maintains MPL in an inactive form in the absence of cytokine. The most frequent 
mutations are the substitution of W515 to L and K found in 3-5% of ETs and PMFs. Of note, 
it is the loss of tryptophan, but not the acquisition of a particular residue that induces 
constitutive activation of MPL,4 leading to the MPN phenotype. Less frequently, the S505N 
mutation located in the exon 10 coding for the transmembrane domain induces a dimerization 
of the transmembrane helix in an active conformation.5 This last mutation has been initially 
found in some hereditary thrombocytosis,6 but has also been detected in rare sporadic ETs and 
PMFs.7,8 In addition, other MPL mutants have already been described, more particularly in 
the extracellular domain of MPL in very rare ETs and PMFs, but without providing evidence 
for a gain-of-function.8-12 SH2B3 loss-of-function mutations, are present in less than 1% of 
ET and PMF, but may not be sufficient to induce a MPN.13,14  
Recurrent mutations in the exon 9 of CALR have been recently found in around 25% of 
ETs and PMFs. They all induce a frameshift leading to a new C-terminus peptide composed 
of at least 35 amino acids with loss of the endoplasmic reticulum (ER) retention signal, 
KDEL.15,16 Whereas wild type CALR is essentially involved in the quality control of proteins 
and in calcium storage in the ER,17 the CALR mutants are able to activate the JAK2/STAT 
pathway via an unknown mechanism like the other MPN driver mutations.15 The same 
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signaling mutations are found in ETs and PMFs underscoring they have a close pathogenesis 
requiring MK hyperplasia although they are clinically different diseases.15,16  
Presently the ETs and PMFs, which are negative for JAK2V617F, CALR and MPL 
mutations are called “triple negative” MPNs.1 However, the entire sequence of MPL is not 
usually examined in patients. Depending of the particular clinical centers, there is a wide 
variety of MPL mutations that are screened (MPLW515K/L or all substitutions of W515 or 
mutations on exon 10 including MPLS505N). Usually only MPLW515K/L are searched by 
allele specific PCR. Whereas the triple negative PMF have a poor prognosis,18,19 triple 
negative ETs have a good prognosis. However, it is presently unknown whether these triple 
negative MPNs are a homogeneous entity. 
In this study we have investigated using Whole Exome Sequencing (WES) the mutational 
profile of 17 triple negative ET patients previously identified as negative for JAK2, MPL and 
CALR mutations. This group was heterogeneous with 7 cases that did not display any clonal 
mutations. In the other cases there was enrichment in SH2B3 and atypical MPL mutations 
located in the exons 10 and 4 (MPLS204P). NGS targeted on MPL and JAK2 exons in 5 of 
these patients and 26 additional patients lead to the discovery of a second MPLS204P 
mutation not seen in WES and another atypical MPL mutation (MPLY591N). Sensitive 
functional studies revealed that both were low gain-of-function mutants. Our results 
demonstrate that some clonal non-canonical MPL gain-of-function mutations are associated 
with triple negative ETs.  
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Material and Methods   
Patient cohort 
Blood samples were obtained from Saint Louis Hospital and Saint Antoine Hospital (Paris) 
and Brest CHU and approved by the local Ethics Committees. Written informed consent was 
in accordance with the Declaration of Helsinki. For most of the patients, the diagnosis was 
performed according to the WHO recommendation including a bone marrow biopsy.20,21 
MPLW515K/L and JAK2V617F genotyping were performed by allele-specific q-PCR.22,23 The 
mutational status of CALR was determined using previously described high-resolution sizing 
of fluorescent dye-labeled PCR amplification of exon 9 and Sanger sequencing for 
validation.24 Plasma TPO levels were measured by Enzyme-Linked ImmunoSorbent Assay according 
to the manufacturer’s instructions (R&D system, Lille, France).  
 
CGH arrays 
CGH arrays from granulocytes were conducted on human CGH 2x400K (G4448A) by 
hybridization of sample versus normal-matched commercial reference and a hierarchical 
clustering was performed 25.  
 
Whole Exome Sequencing  
WES was performed on genomic DNA (1 μg) from paired samples (granulocytes versus T 
cells) The final libraries were indexed, pooled and sequenced on Illumina HiSeq-2000 
sequencer. Only non-synonymous and splice-site mutations were further pursued. A special 
analysis using BWA ALN for mapping and GATK HaplotyCaller allowed us to detect 
insertions and deletions. Candidate mutations observed in the exon sequencing were validated 
using Sanger sequencing 15,16,26. 
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MPL and JAK2 gene sequencing:  
Ion AmpliSeq™ Custom Panel Primer Pools for MPL and JAK2 were used (10 ng of gDNA 
per primer pool) to perform multiplex PCR but the protocol to generate libraries was modified 
by adding paired-end adaptors (NEXTflex, Bioo Scientific) to sequence in an Illumina MiSeq 
flow cell using the onboard cluster method, as paired-end sequencing (2x250 bp reads) 
(Illumina, San Diego, CA). The entire MPL and JAK2 exons were sequenced to reach a 1000x 
depth. Minimum variant frequency was set at 1%. Sanger sequencing of the CD3+ DNA 
assessed the somatic status of the mutation. 
 
Cell lines and cell culture 
Cytokine-dependent (GM-CSF) human UT7 cell line was cultured in alpha medium 10% SVF, 
and 5 ng/mL GM-CSF. This UT7 cell line did not express MPL and did not response to TPO. 
IL-3 dependent murine pro-B Ba/F3 cells were cultured in Dulbecco medium with 10% SVF 
and 5%WEHI.  
 
DNA manipulations, production of retroviruses 
The 1531T>A (Y591N), 610T>C (S204P) point mutations were introduced into the MEGIX-
human MPL-IRES-GFP plasmid by the site-directed mutagenesis method using the PfuUltra 
high-fidelity DNA polymerase (Stratagene, Agilent Technology, les Ulis, France). Vesicular 
stomatitis virus glycoprotein (VSV-G) pseudotyped viral particles were produced into 
293EBNA cells as previously described 27. 
 
Flow Cytometry 
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Cells were labeled with a monoclonal anti–HA antibody conjugated to PE or an isotype 
control. APC-Annexin V staining was performed according to the manufacturer 
recommendations (Becton Dickinson (BD), Le Pont de Claix, France). For cell cycle analysis, 
cells were treated with lysis buffer (sodium acetate with Triton X-100), RNAse and labeled 
with propidium iodide for 30 min.  Cells were analyzed on a LSR2 flow cytometer (BD). Data 
were analyzed with Flow Jo software. 
 
Confocal microscopy 
Cells (100,000) were plated on polylysine slides, fixed with 4% paraformaldehyde for 10 min, 
permeabilized with 0.2% Triton. Primary monoclonal antibodies against GM130 and CALR 
(Abcam, Cambridge, UK) and HA (Covance, (Eurogenec, Seraing, Belgium) were incubated 
in BSA 0.2% solution for 1 h followed by secondary goat anti-mouse (Alexa 546) or anti-
rabbit (Alexa 633) antibodies (Life technologies, Saint-Aubin, France). DAPI was used to 
label nuclei. Cells were analyzed using a confocal Leica microscope. 
 
Western Blotting 
Signaling studies were performed on UT7 and Ba/F3 cell lines by Western blot analysis of 
JAK2 (Tyr 1007/1008), STAT1 (Tyr 701), STAT3 (Tyr 705), STAT5 (Tyr 694), ERK1/2 
(Thr 202/Tyr 204) and AKT (Thr 308) and of these different pan proteins (Cell Signaling 
Technology (Ozyme, Saint Quentin en Yvelines, France)). HSC70 (Stressgen, Victoria, 
Canada) or ß-Actin (Sigma, Saint Quentin Fallavier, France) serves as loading control. 
 
STAT5 reporter assay 
Gamma 2A JAK2-deficient cells 28 were transfected with cDNA coding for MPL or MPL 
mutants, STAT5, JAK2, Spi-Luc (STAT5 transcriptional reporter) and pRL-TK. 29,30After 5 h 
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the cells were stimulated with 10 ng/mL human TPO. Cells were lysed from 24 h to 48 h later 
and the luciferase activity was measured, as described. 4 
 
Cell proliferation 
30,000 cells/mL were seeded in a 96 well plate with TPO or GM-CSF at various 
concentrations. Cell proliferation was quantified 3 days later using WST-1 assay (Takara 
(Ozyme)) 31. Experiments were done in triplicate. Dose-response curves to TPO were 
expressed as percent of viability of the maximal response. 
 
Colony formation assay 
Twenty cells per well were sorted in a 96 well plate. For each condition, we filled 1 plate with 
GM-CSF at 5 ng/mL and 8 plates without cytokine. After 3 days, 5 ng/mL GM-CSF or 
10 ng/mL TPO were added to perform rescue experiments in half of the plates grown without 
cytokine. Colony formation was counted at day 8. Each experiment was repeated three times, 
but the TPO addition was performed in only one experiment. 
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Results  
WES and overview of genetic alterations  
We studied 17 patients diagnosed as triple negative ETs namely negative for any 
JAK2V617F, MPLW515K/L and CALR exon 9 mutations. We performed WES on paired 
granulocyte and T cell samples that were considered as the tumoral and control cells, 
respectively. The sequencing coverage mean was 110x and 75% of the target sequences could 
be analyzed with a coverage above 15x. All candidate mutations with a p<0.05 generated by 
the bioinformatics analysis were verified by Sanger sequencing. 
Sanger sequencing confirmed 22 missense, 4 nonsense and 2 splice mutations, and 3 
frame-shifting indels leading to a total of 31 mutations out of 80 candidates. The mutation rate 
per sample was low (1.82), even in comparison to other myeloid malignancies (Supplemental 
Table S1). Furthermore, CGH arrays performed on 5 samples were normal.  
In a first analysis, three patients displayed previously described MPL mutations including 
two in exon 10 (MPLW515R and MPLS505N) and one in exon 4 (MPLS204P) (Figure 1B). A 
homozygous nonsense mutation in the SH2B3 gene was identified in one patient. The 
unexpected identification of known MPL mutations led us to perform deep re-sequencing of 
all MPL and JAK2 exons resulting in the detection of JAK2V617F in one patient and again a 
MPLS204P mutation in another patient (Figure 1C, Supplemental Table S2). These mutations 
were not seen in WES because of low allelic burden for the JAK2 mutation (<5%) and low 
depth of coverage at this position for the MPLS204P.  
No signaling mutations were identified in the remaining eleven ET patients (Figure 1A). We 
divided them in clonal and non-clonal disorders, as performed in several previous studies. 32-35 
Four of them showed a clonal hematopoiesis in granulocytes based on the presence of non-
recurrent mutations of unknown function. Seven patients had no detectable clonal mutations 
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suggesting the presence of a polyclonal hematopoiesis in granulocytes. Neither CALR exon 9 
mutations nor JAK2V617F could be detected in their platelets (data not shown). 
Noteworthy, the two MPLS204P–positive samples were associated with other mutations: one 
displayed three other mutations including another driver mutation ASXL1 and the second 
presented five mutations different from known MPN driver mutations, but with a mutation of 
the RNA helicase HELZ, which may play a role in oncogenesis (Table 1). The patient 
identified with an acquired MPLS505N mutation (absent in T cells) also exhibited a mutation 
in SRSF2 with a higher variant allele frequency suggesting that MPLS505N was a secondary 
event  (Table 1). Of interest, this case presented some myelodysplatic features detected by 
pathology associated with a slight increase in blast count in a bone marrow aspirate. This 
patient was re-classified as a MDS with a thrombocytosis rather than as a true ET patient. 
Finally, there was a case exhibiting both homozygous non-sense SH2B3 and SF3B1 mutations 
(Table 1) without any noticeable increase in ring sideroblasts or sign of MDS at bone marrow 
aspiration, thus eliminating a RARS-T. 
Taken together these data indicated that atypical MPL mutations seem to be recurrent in 
the so-called triple negative ET. NGS targeted on MPL and on JAK2 was performed on 31 
patients including 5 ETs studied in WES and 26 additional less well-characterized ETs. 
Another mutation of MPL with a variant allele frequency of 9.28% was detected. This 
missense MPL mutation (c.1351T>A) leads to the substitution of a tyrosine by asparagine in 
the cytosolic domain (Y591N). We also detected a missense mutation in JAK2 (N1108S) with 
a variant allele frequency of 50% in both the granulocytes and the T cells. Sequencing of hair 
DNA confirmed it was a germline mutation (Figure S1). The c.3323A>G has been reported as 
a rare polymorphism (0.36%). However, the 3D modeling of JAK2N1108S predicts that it 
may provide a slight gain-of-function based on a higher propensity of formation of a tighter 
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hydrogen bond between S1108 and N1085, which is linked to the active state of JAK2 kinase 
domain (Figure S2).  
 
Functional analysis of the MPLS204P mutant 
In one of the two MPLS204P-positive patients we examined TPO level that was in the 
normal range (12 pg/mL, normal <30 pg/mL) and comparable to other ETs (range: 8.25-96.1 
pg/mL). To study cell surface localization of MPL, we transduced the human factor-
dependent UT7 cell line with the HA-tagged MPLWT- and MPLS204P-expressing retrovirus 
(IRES-GFP). At similar GFP levels, the mean fluorescence intensity of HA labeling was 
comparable for both receptors using flow cytometry (Figure 2A). Expression of MPLS204P at 
the cell surface was further confirmed by Western Blotting. A 85 kDa Endoglycosidase-H 
(Endo-H)-resistant band corresponding to the mature form of MPL was detected for MPLWT 
and MPLS204P (Figure 2B). The subcellular localization of the two receptors was examined 
by confocal microscopy. They had a similar localization in the ER (anti-CALR antibody) and 
Golgi (anti-GM130 antibody) compartments (Figures 2C and D). Finally, we studied the 
internalization of the receptors after TPO addition using the Ba/F3 cell line. No difference 
was observed between the MPLWT and MPLS204P  (Figure 2E). Taken together, these 
results suggest that the thombocytosis was not related to a defect in cell-surface localization 
of MPLS204P, which would have induced a loss of TPO clearance activity.  
We studied the effects of MPLS204P on cell proliferation. MPLS204P did not induce 
cytokine-independent growth nor it renders cells hypersensitive to TPO or GM-CSF 
hypersensitivity (Figures 3A and B). In addition, we could not find any difference in 
apoptosis in the presence (Figure 3C) or absence (Figure 3D) of TPO or in cell cycle at 
different TPO doses (Figure 3E). No constitutive activation in STAT3, STAT5 and AKT was 
observed in UT7 cells expressing MPLS204P (Figure 4A). These results suggest that 
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MPLS204P is a weak gain-of-function mutant. We further used a more sensitive technique to 
ask whether the MPLS204P was able to support TPO-independent JAK/STAT signaling like 
MPLW515K.4 We employed a luciferase reporter assay for STAT5 activation induced via 
MPL in the JAK2-deficient gamma2A cells.4 Expression of MPLS204P supported TPO-
independent JAK2/STAT5 signaling, albeit to lower levels than MPLW515K (Figure 4B). Of 
interest, while MPLW515K-induced JAK2/STAT5 activation was evident at 24-30 h after 
transfection, a longer period was necessary for MPLS204P (> 40 h). This indicates that the 
MPLS204P mutant signals are weaker than those induced by MPLW515K.  
Finally, we tested whether MPLS204P could induce prolonged signaling in UT7 cells. 
Cells were stimulated with 10 ng/mL TPO, subsequently washed and then cultured without 
cytokine for 3 h. A sustained phosphorylation of STAT5 and AKT was observed for the 
mutant cells (Figure 4C). To demonstrate that this weak constitutive activity exerts some 
biological consequence a limiting dilution of MPLWT and MPLS204P UT7 cells (twenty 
cells per well in a 96-well plate) were grown without cytokine for one week (Figure 5A). 
Autonomous growth numbered as colonies was observed with UT7 MPLS204P (5%-10%), 
but not with UT7 MPLWT, except in rare wells suggesting that around 0.25% of UT7 cells 
became cytokine-independent due to MPLS204P.  Furthermore, after 3 days of culture 
without cytokines we added GM-CSF or TPO for rescue, and observed a 2 to 4-fold increased 
cloning efficiency for UT7 MPLS204P compared to MPLWT (Figures 5B and C).  
Altogether these results demonstrate that MPLS204P is a gain-of-function mutant.  
Functional analysis of the MPLY591N mutant 
We conducted the functional analysis of another MPL mutant identified by NGS using 
Ba/F3 cells lines. Flow cytometry analysis showed that MPLY591N was addressed more 
efficiently (1.63±0.07 fold) to the cell surface membrane compared to MPLWT at similar 
GFP levels (Figure 6A), indicating either an increased trafficking of MPL mutant to cell 
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surface or a decreased internalization. We measured the impact of this mutant on cellular 
proliferation in response to TPO. MPLY591N conferred a 4- to 5-fold hypersensitivity to 
TPO compared with MPLWT (IC50 of 0.10 ng/mL for WT and 0.02 ng/mL for Y591N), but 
without spontaneous growth in the absence of cytokine (Figure 6B). 
We next verified the effect of MPLY591N mutant on signaling in Ba/F3 cells by Western 
Blot analysis. Noticeably, these cells expressed similar levels of exogenous MPL. 
Interestingly, a constitutive phosphorylation of STAT3, STAT5 and ERK was observed in 
MPLY591N mutant cells compared with MPLWT cells. The TPO dose-dependent increase in 
the phosphorylation of these molecules was higher in presence of MPLY591N than MPLWT. 
No difference was observed on AKT or STAT1 phosphorylation (Figure 6C).  
Altogether, these results show that MPLY591N is also a weak gain-of-function mutation 
that leads to TPO hypersensitivity without independent growth and to a partial spontaneous 
activation of signaling pathways. 
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Discussion 
The goal of this work was to characterize the mutational genomic profile of triple negative 
ETs using WES. Among the 17 triple negative ETs, we considered that 7 had a polyclonal 
hematopoiesis in granulocytes as no mutation was detected by WES. This molecular approach 
has clear limitation because it cannot detect mutations in non coding sequences and gene 
fusion and even more cannot detect mutations in coding sequences at low variant allele 
frequency (VAF). In this work, we defined clonal hematopoiesis as the presence of any 
somatic mutation either in a known driver of hematopoietic malignancies or in another gene 
(passenger mutation),32-35 but without using X chromosome inactivation assays except in two 
cases where results were concordant.  It has been calculated that each normal HSC 
accumulates 0.13 mutation per year in coding sequences 36. Thus, it expected that in the case 
of clonal hematopoiesis in patients older than 50, several mutations would be found.  
However, the technique has a sensitivity of around 10% for VAF. Thus, it seems likely that 
this “polyclonal” triple negative thrombocytosis cases can be MPNs with a low VAF in 
granulocytes similar to JAK2V617F ET in which VAF is much higher in platelet RNA than in 
granulocyte DNA 37. Therefore, it will be important in the future to directly perform WES or 
whole genome sequencing on megakaryocyte or to sequence platelet RNA. Alternatively, 
some of these disorders can be other diseases than MPNs, more particularly hereditary 
thrombocytosis. In the co-submitted paper, germline gain-of-function mutations in JAK2 and 
MPL were found in triple negative ETs. 38 Hereditary thrombocytosis may arise without other 
familial cases if the patient is the founder. In one case, we detected a germline mutation in 
JAK2 (N1108S) that appears in in silico modeling as a possible gain-of-function mutation, 
suggesting a hereditary thrombocytosis. However this mutation has also been described as a 
rare polymorphism. Thus we cannot exclude that rare JAK2 or MPL variants, which may be 
present in the general population, can induce a MPN disease in certain individuals.  
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The enrichment in previously described rare signaling mutations, 9 was striking in triple 
negative ETs. One was a homozygous nonsense mutation in SH2B3. Heterozygous SH2B3 
mutations were reported in MPNs and it is discussed whether by themselves they could give 
rise to a MPN. 14 In some cases they are associated with JAK2V617F. 39 Here, the mutation is 
homozygous and because mice totally deficient in Sh2b3 develop a myeloproliferative 
disorder, 40 we can suggest that this homozygous mutation leading to an absence of LNK was 
really the driver of the MPN. Interestingly, a SF3B1 mutation was associated with this 
homozygous SH2B3 mutation, but the phenotype of the disease was an ET.  
Four mutations in MPL were found in the first series of patients, including MPLS505N 
and MPLW515R located in exon 10 that are not commonly screened. The later were somatic 
mutations in our study although they can also be identified as germline mutations in 
hereditary thrombocytosis. 6,41   
In two other patients we detected an acquired MPLS204P mutation. This mutation has 
been previously described in a myelofibrosis, and a S204F mutation was described in another 
myelofibrosis case. 10,12 In the co-submitted manuscript paper, S204P and S204F mutations 
were detected in two triple negative patients. 38It is interesting to note that mouse MPL 
residue 204 is a proline instead of a serine in human MPL, thus the S204P mutation restores 
the mouse MPL sequence into the human MPL. Moreover, the germline mutation K39N 
(MPL Baltimore) present in a heterozygous form in 7% of African-American population also 
restores a mouse sequence and is associated with a thrombocytosis.42 It is tempting to assume 
that differences between the human and mouse MPL sequences may contribute to the high 
platelet count in mice associated with an elevated plasma TPO level in comparison to the 
situation in humans. In the case of the K39N, there is evidence that the membrane expression 
level of the MPL mutant is lower than MPLWT and this can explain a thrombocytosis 
phenotype due to a decreased TPO clearance activity of MPL, which is in great part related to 
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the expression level of MPL on the surface of mature megakaryocyte and platelets.42 This has 
been well demonstrated in 3 murine models.43-45 Here, we clearly demonstrate that the 
thrombocytosis induced by MPLS204P is not due to a defect in cell trafficking of the receptor. 
In contrast, MPLS204P is a weak gain-of-function mutant in signaling, inducing a constitutive 
STAT activation using sensitive approaches and an increased and more prolonged ligand-
induced STAT phosphorylation than MPLWT. Using limiting dilution techniques, it was 
possible to demonstrate that MPLS204P could induce cytokine-independent growth with a 
low efficiency in around 1/400 UT7 cells. Furthermore, UT7 MPLS204P cells were more 
resistant than UT7 MPLWT cells to a 3-day cytokine deprivation. The two cases with 
MPLS204P were associated with several other mutations: one with ASXL1, the second with a 
mutation in an RNA helicase implicated in proliferation. Thus, we suspect that these mutants 
with a very low oncogenic potential, would need to be associated to other drivers to give rise 
to a MPN.  
Finally, we detected a MPLY591N mutant in one patient. MPLY591D has been 
previously described in a PV patient in association with a heterozygous JAK2V617F mutation 
10
 as reported in the co-submitted manuscript. Here, we detected the MPLY591N in the 
absence of a JAK2 mutation. This mutation was assumed to be a gain-of-function for two 
reasons. Previously it was shown that this tyrosine also called 78 (intracellular tyrosine) is 
phosphorylated on the MPLW515A and that the double mutant MPLW515A/Y591F induced 
a much more severe MPN in the mouse than the single MPLW515A mutant.46 Furthermore, 
this tyrosine is also phosphorylated after TPO binding, and negatively regulates MPL 
signaling by promoting its internalization degradation as well as ERK signaling.46,47 48 
Asparagine is a polar residue in contrast to the negative charge represented by tyrosine 
phosphorylation and thus the Y591N mutation resembles a Y591 loss-of-function, like Y591F, 
but possibly weaker since unlike phenylalanine, asparagine is polar. When the Y591N mutant 
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was expressed in Ba/F3 cells it induced a slight TPO hypersensitivity, which was associated 
to a constitutive activation of STAT3 and ERK. In the MPLY591N–positive patient, we did 
not perform WES to assess whether other driver mutations were present, as for MPLS204P. 
However, this mutant was detected in a case of ET occurring in a familial form of MPN 
where we have recently identified the predisposition locus consisting of a 700-kb duplication 
involving 6 genes. The overexpression of two of them, ATG2B and GSKIP, induces TPO 
hypersensitivity and cooperates with JAK2, MPL and CALR mutations to give an ET.25 Thus, 
the predisposition locus could be the initiating event and the low gain-of-function 
MPLY591N could be sufficient to induce an overt ET.  
Altogether this study has shown that in a fraction of the so-called triple negative ETs a 
significant proportion of patients have mutations in signaling molecules, more particularly in 
MPL. This group of patients appears heterogeneous including some with a polyclonal 
hematopoiesis as previously shown in pediatric ETs.49 Further studies using whole exome 
sequencing and RNA sequencing will be required to better understand the pathogenesis of 
these ETs.  
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Figure legends 
Figure 1: Genomic analysis 
A) A schematic representation of the signaling mutations in the 17 patients and of the type 
of hematopoiesis in triple negative ETs. We consider as polyclonal ETs the patients that 
exhibit no mutation (driver or passenger) in WES. B) Sanger sequencing of MPLS204P. 
Nucletotides and amino acid numbers are indicated. 
 
Figure 2: MPLS204P does not exhibit cellular trafficking defects  
A) MPL cell-surface expression analysis by flow cytometry. UT7 cells transduced with either 
the HA-tagged MPLWT or HA-tagged MPLS204P receptor were incubated with an anti-HA 
antibody coupled with PE. Histograms show equivalent GFP expression (left) monitoring the 
total MPL levels and HA-PE labeling (right) corresponding to similar cell-surface expression 
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of MPLWT and MPLS204P. B) Analysis of the different forms of MPL. UT7 MPLWT and 
MPLS204P cell extracts were treated with EndoH (500 U, overnight at 37°C) and Western 
blot analysis was performed using anti-HA antibody. Figure shows the different forms of 
MPL with EndoH-resistant mature form corresponding to a 85 kDa band which is equivalent 
in both cell lines. Samples were run on the same gel and vertical lines have been inserted to 
indicate a repositioned gel lane. C) Localization of MPL in the endoplasmic reticulum (ER) 
and D) in the Golgi apparatus. MPLWT and MPLS204P UT7 cells were analyzed by 
immunofluorescence using an anti-CALR (ER marker), an anti-GM130 (Golgi apparatus 
marker) and an anti-HA (MPL detection) antibodies. E) Internalization of the MPLWT and 
MPLS204P after TPO binding. These experiments were performed with Ba/F3 cells 
expressing either MPLWT or MPLS204P. MPL cell surface expression was studied by flow 
cytometry after TPO addition. Results are means±SD of 3 independent experiments.  
 
Figure 3: MPLS204P does not present proliferative advantage in bulky cultures 
A and B) Cell proliferation induced by TPO of MPLWT and MPLS204P UT7 cells. Cells 
were cultured in the presence of various concentrations of TPO (A) or GM-CSF (B) for 72 h. 
Viable cells were quantified by WST-1 proliferation assay. Dose-response curves are means± 
SEM (n=3 in triplicate). C and D) Apoptosis analysis in MPLWT and MPLS204P UT7 cells. 
(C) Cells were cultured for 2 days with various concentration of TPO (0.01, 0.05 and 10 
ng/mL) and the percentage of apoptotic cells (Annexin V positive) was analyzed by flow 
cytometry using Annexin V assay. (D) Cells were cultured for 24 h with TPO (10 ng/mL) 
followed by overnight deprivation. The percentage of apoptotic cells (Annexin V-positive) 
was analyzed at different times after TPO removal (1, 2, 3 and 4 days). E) Cell cycle analysis 
of MPLWT and MPLS204P UT7 cells. Cells were cultured for 2 days with various 
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concentration of TPO (0.01, 0.05 and 10 ng/mL) and the percentage of cells in G1, S and G2 
phases were determined after propidium iodide labeling, by flow cytometry analysis. 
 
Figure 4: MPLS204P is a weak gain-of-function mutant 
A) Signaling studies induced by high TPO concentration in MPLWT and MPLS204P UT7 
cells. After cytokine deprivation, cells were stimulated with TPO (100 ng/mL for 5 min, 30 
min or 2 h). The phosphorylation status of STAT3, STAT5, AKT and ERK1/2 was examined 
by Western blotting and results were compared to cells stimulated by GM-CSF (5 ng/mL). B) 
STAT5 transcriptional activity in Gamma 2A JAK2-deficient cells expressing MPLWT or 
MPLS204P. Cells were transfected with cDNAs coding for MPLWT or MPLS204P, JAK2, 
STAT5 and with Firefly STAT5 luciferase reporter spi-Luc and pRL-TK vectors coding for 
renilla luciferase. Luminescence was measured after 48 h transfection. Shown are average 
units±SEM of one representative experiment performed in triplicate out of three. C) 
Persistent signaling in UT7 MPLS204P. UT7 MPLWT and UT7 MPLS204P were 
stimulated by TPO (10 ng/mL) for 10 min and subsequently washed.  A 3 h time-course was 
performed followed with Western blotting, as in previous figures. MPLWT and MPLS204P 
samples were run on the same gel. P-STAT5/STAT5 or P-ERK/ERK ratios are indicated after 
quantification by image J software. 
 
Figure 5: UT7 MPL S204P cells are less cytokine-dependent than UT7 MPL WT. 
A) Growth of UT7 MPLS204P and UT7 MPLWT at limiting dilution without cytokines. 
Cells (20 per well) were cultured without cytokines in a 96-well plate. Colony growth were 
counted one week later. B) Rescue experiments by GM-CSF. Cells (20 per well) were 
cultured without cytokines in a 96-well plate. After 3 days, GM-CSF (5 ng/mL) was added 
and colonies were counted one week later. C) Rescue experiments by TPO. Cells (20 per 
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well) were cultured without cytokines in a 96-well plate. After 3 days, TPO (10 ng/mL) was 
added and colonies were counted one week later. Results represent the means±SD of the 
number of colonies /96-well plate. Each point corresponds to number of clone in one plate.  
 
Figure 6: Analysis of the MPLY591N mutant. 
A) MPL cell-surface localization in Ba/F3 cells. Ba/F3 cells expressing the bicistronic 
retroviral pMEGIX-IRES-GFP vector encoding HA-tagged MPLWT or MPLY591N and GFP 
were maintained in IL3-supplemented medium. Flow cytometry analysis was assessed and 
histograms show equivalent GFP expression (left) monitoring the total MPL levels and HA-
PE labeling (right) corresponding to cell-surface expression of MPLWT and MPLY591N. B) 
Sensitivity to TPO of Ba/F3 cells. Ba/F3-MPLWT or MPLY591N cells were cultured for 72 
h either in absence of cytokine (black arrow, X axis) or in presence of increasing doses of 
TPO (0.01, 0.1, 1 and 10 ng/mL). Viable cells were quantified by WST-1 proliferation assay. 
Dose-response curves are means expressed in percentages of maximum growth value ±SEM 
(n=3 in triplicate). Two-tailed t-test,*<0.05 **, p<0.01. C) Signaling studies in Ba/F3-MPL 
cells. Ba/F3-MPLWT or MPLY591N cells were serum- and cytokine-starved for 6 h prior to 
a 15 min stimulation without or with TPO (0.01, 0.1, 1 and 10 ng/mL) as indicated. Cells 
were lysed and the phosphorylation status of STAT1, STAT3, STAT5, AKT and ERK1/2 was 
examined by Western blotting with the respective anti-phospho specific antibodies, as 
indicated. MPL expression was also verified. Expression ofβ actin in the samples was used as 
loading control and was consistent with expression of total AKT, ERK1/2 and the individual 
STAT isoforms. Blots shown were reproduced in three independent experiments.  
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Table 1: Mutational profile in granulocytes from 10 ET patients by exome sequencing. 
The % of variant allele frequency is indicated in brackets. 
Sample Mutations   
3 
SCNN1G 
(21.34)           
12 
SHOC2 
(22.22) 
CASC5 
(25.0)         
14 
MPL S204P 
(19.26)  
ASXL1 
(20.97) 
EDA 
(41.18)       
21 
KPNA1 
(28.21) 
VPS13D 
(39.29) 
EEA1 
(39.79) 
SF3B1 
(54.55) 
SH2B3 
(98.33) 
  
24 
FUBP1 
(23.88) 
PPP1R3
7 (30.77) 
COMP 
(36.14) 
ADCY5 
(36.67) 
HELZ 
(37.25) 
MPL 
S204P 
(47.74) 
25 
ATXN7L1 
(21.95)           
32 
LYZL2 
(30.77)   
 
      
91 
MPL S505N 
(23.02) 
DDI1 
(24.18) 
IMPG2 
(24.24) 
PPP2R5
A (43.75) 
SRSF2 
(44.35) 
APOL4 
(86.52) 
92 
JAK2 
V617F 
(11.77) 
ALDH3A
2 (28.12)         
98 
MPL 
W515R 
(23.94) 
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